Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 20 |
| Dec 2025 | 0 | 15 |
| Jan 2026 | 0 | 12 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 22 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2022 Filed Oct 18, 2022 22:52 UTC |
Scharen-Guivel Hilda FrederiqueDirector
|
GrantRestricted Stock Units · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000621 · form4.xml · derivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:07 UTC |
ALLEN MONTY KDirector
|
SaleCommon Stock | 3,072 | $37.71 | $115,845.43 |
DisclosureSEC source: 0000898432-22-000511 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,928 F1 · price: This transaction was executed in one trade at $37.7101. Read SEC document |
| June 20, 2022 Filed Jun 23, 2022 12:35 UTC |
GLENN JOHNChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 23.183 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000409 · form4.xml · derivative · entry 1 GLENN JOHN · CIK 0001253497 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23.183 Underlying: Common Stock · 23.183 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 20, 2022 Filed Jul 8, 2022 21:01 UTC Amendment |
GLENN JOHNChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 23,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000462 · form4.xml · derivative · entry 1 GLENN JOHN · CIK 0001253497 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,183 Underlying: Common Stock · 23,183 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.underlying_shares: This Form 4/A is being filed solely to correct administrative errors in (i) the number of shares of Common Stock underlying Restricted Stock Units shown as acquired and beneficially held by the reporting person and (ii) the vesting commencement date of such Restricted Stock Units in his Form 4 filed on June 23, 2022 (the "Original Form 4"). All other information set forth in the Original Form 4 remains correct. Read SEC document |
| May 03, 2022 Filed May 4, 2022 23:10 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $33.53 | $335,298.00 |
DisclosureSEC source: 0000898432-22-000322 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 622,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.14 to $34.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 21:32 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $40.50 | $404,996.00 |
DisclosureSEC source: 0000898432-22-000316 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 632,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.52 to $41.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 11:43 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $43.90 | $439,023.00 |
DisclosureSEC source: 0000898432-22-000288 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 642,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.44 to $43.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 21:46 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $42.90 | $429,012.00 |
DisclosureSEC source: 0000898432-22-000273 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 652,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.44 to $43.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:08 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $45.35 | $453,530.00 |
DisclosureSEC source: 0000898432-22-000265 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 662,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.50 to $45.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 11:38 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $52.95 | $529,546.00 |
DisclosureSEC source: 0000898432-22-000229 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 672,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.10 to $54.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 20:09 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $50.08 | $500,802.00 |
DisclosureSEC source: 0000898432-22-000223 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 682,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.70 to $50.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 11:39 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $46.65 | $466,547.00 |
DisclosureSEC source: 0000898432-22-000222 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 692,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.67 to $48.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 23:26 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.04 | $470,353.00 |
DisclosureSEC source: 0000898432-22-000219 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 702,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.17 to $49.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $49.26 | $492,554.00 |
DisclosureSEC source: 0000898432-22-000210 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 712,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.32 to $50.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 00:29 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.00 | $469,959.00 |
DisclosureSEC source: 0000898432-22-000198 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 722,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.54 to $47.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 01:31 UTC |
ALLEN MONTY KDirector
|
SaleCommon Stock | 1,000 | $47.01 | $47,013.80 |
DisclosureSEC source: 0000898432-22-000125 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $46.95 to $47.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:10 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.15 | $471,506.00 |
DisclosureSEC source: 0000898432-22-000121 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 732,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.13 to $48.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,441 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,441 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC |
HAWKINS JAMES BDirector
|
SaleCommon Stock | 9,441 | $50.22 | $474,145.90 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 F2 · price: This transaction was executed in multiple trades at prices ranging from $50.20 to $50.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 9,441 | $1.48 | $13,972.68 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,931 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 12, 2022 02:34 UTC |
Scott Christopher K.CFO & Secretary
|
SaleCommon Stock | 19,286 | $50.06 | $965,424.37 |
DisclosureSEC source: 0000898432-22-000100 · form4.xml · nonDerivative · entry 1 Scott Christopher K. · CIK 0001613803 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,710 F1 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and priced at which the transaction was effected. Read SEC document |
| February 10, 2022 Filed Feb 12, 2022 01:19 UTC |
VUOTO ANTHONYDirector
|
SaleCommon Stock | 3,937 | $50.95 | $200,602.75 |
DisclosureSEC source: 0000898432-22-000099 · form4.xml · nonDerivative · entry 1 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,121 F1 · price: This transaction was executed in multiple trades at prices ranging from $50.20 to $51.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 21:09 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.44 | $474,434.00 |
DisclosureSEC source: 0000898432-22-000079 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 742,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.10 to $48.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:43 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $39.44 | $394,417.00 |
DisclosureSEC source: 0000898432-22-000076 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 752,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.07 to $40.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 21:09 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $37.06 | $370,559.00 |
DisclosureSEC source: 0000898432-22-000065 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 762,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.93 to $39.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 18, 2022 23:54 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $41.21 | $412,056.00 |
DisclosureSEC source: 0000898432-22-000035 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 772,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.42 to $43.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:06 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $44.54 | $445,379.00 |
DisclosureSEC source: 0000898432-22-000034 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 782,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.59 to $45.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 22:39 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $48.56 | $485,629.00 |
DisclosureSEC source: 0000898432-22-000015 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 792,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.26 to $49.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:35 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $47.11 | $471,073.00 |
DisclosureSEC source: 0000898432-21-000946 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 826,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.78 to $47.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 27, 2021 Filed Jan 4, 2022 22:37 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000014 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 802,950 Read SEC document |
| December 27, 2021 Filed Jan 4, 2022 22:37 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
GiftCommon Stock | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000014 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 803,450 Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:41 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 10,000 | $44.38 | $443,800.00 |
DisclosureSEC source: 0000898432-21-000936 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 836,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.84 to $44.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:07 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 3,500 | $44.12 | $154,437.15 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 846,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.06 to $45.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:07 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 1,500 | $44.00 | $66,000.00 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 849,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 21:07 UTC |
Susi Roger E.Director · President, CEO and Chairman · 10% owner
|
SaleCommon Stock | 5,000 | $44.25 | $221,250.00 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 851,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 559 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,441 Underlying: Common Stock · 559 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
SaleCommon Stock | 559 | $48.50 | $27,111.50 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 559 | $1.48 | $827.32 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,049 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
GrantRestricted Stock Units · Derivative | 2,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,071 Underlying: Common Stock · 2,071 shares Expires not disclosed F4 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F5 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 4,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 18,743 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
Exercise / conversionCommon Stock | 4,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
SaleCommon Stock | 18,743 | $47.07 | $882,289.24 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F2 · price: This transaction was executed in multiple trades at prices ranging from $46.30 to $48.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
HAWKINS JAMES BDirector
|
GrantCommon Stock | 18,743 | $1.48 | $27,739.64 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,011 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:42 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000773 · form4.xml · derivative · entry 5 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On December 7, 2020, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: On December 7, 2020, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:42 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,185 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000773 · form4.xml · derivative · entry 4 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,185 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 7, 2019, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: On December 7, 2019, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:42 UTC |
ALLEN MONTY KDirector
|
GrantRestricted Stock Units · Derivative | 2,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000773 · form4.xml · derivative · entry 3 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,071 Underlying: Common Stock · 2,071 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:42 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 2,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-21-000773 · form4.xml · nonDerivative · entry 2 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:42 UTC |
ALLEN MONTY KDirector
|
Exercise / conversionCommon Stock | 2,185 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-21-000773 · form4.xml · nonDerivative · entry 1 ALLEN MONTY K · CIK 0001253352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC |
VUOTO ANTHONYDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000771 · form4.xml · derivative · entry 5 VUOTO ANTHONY · CIK 0001222060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.